In July 2014, ASCO President Peter Paul Yu, MD, FACP, FASCO, wrote a lengthy letter to the CEO of the U.S. Pharmacopeial Convention (USP), commenting on the proposal for Chapter <800> regulations, saying “it is not evidence-based and is fundamentally flawed” and urging USP to “engage with ASCO in a more collaborative process before finalizing recommendations in this area.”

In response, USP revised its recommendations and offered them for public comment until May 31. For more information, go to http://www.usp.org/usp-nf/notices/general-chapter-hazardous-drugs-handling-healthcare-settings.

To download the proposed Chapter <800> revisions, go to www.usp.org/sites/default/files/usp_pdf/EN/m7808.pdf.

To read Dr. Yu’s letter, go to www.asco.org/sites/www.asco.org/files/asco_usp_800_comments_final-c-c.pdf. ■